Breast cancer (BC) is the leading cause of cancer-related deaths in young to middle-aged women worldwide. Moreover, the survival rate in BC-patients is only 20% when associated with metastatic disease. The high mortality rate observed in BC women with metastatic disease has precipitated a major challenge revealing an unmet need to develop new therapeutic strategies in treating metastatic cancer. One such approach has involved utilization of chemokines and their receptors as therapeutic targets for cancer metastasis. It has been established that a definitive correlation exists between overexpressed CXCR4 malignant cell receptors and cancer cell growth, invasion, and migration. It is also widely accepted that the CXCR4 receptor, complexed to its CXCL12 ligand, plays a major role in establishing migratory pathway gradients for cancer cells migrating to distant tissues/organ sites. It would follow that chemokine decoy ligands, such as peptide antagonists and inhibitors, could serve to induce receptor blockade and impede subsequent intracellular signaling. Such ligands, synthetic and natural, reportedly contribute to reducing cancer cell growth, invasion, adherence, and migration.
Introduction
Breast cancer (BC) poses the highest incidence among cancer types in women and accounts for 30% of all new cancers in females worldwide [1] . BC is also the leading cause of cancer-related deaths in women especially between ages of 20 to 50 years [2] . When associated with extensive metastasis, BC-associated mortality rises to 80 -90%. Hence, there exists major unmet needs in treating metastatic disease in BC patients, even though new chemo-therapeutic drugs are constantly being developed and assayed for efficacy.
The survival rate in patients with BC metastatic disease approximates 20% of patients after 5 years [3] . Thus, most cancer deaths can be attributed to metastasis rather than the primary tumor mass itself. The present commentary addresses this unmet need by discussing chemokine receptors and ligands as therapeutic targets for cancer growth and metastasis.
Tumor cell metastasis appears to comprise five sequential steps as follows [2, 4] . Fourth, the RNA transcriptome of CTCs has recently been reported revealing that such cells exhibit a semi-dormancy state bent on intravascular survival and maintenance of sufficient cell signaling pathways to maintain basic cell functioning [6, 7] (see below). In contrast, the over-expression of CXCR4 receptor and its CXCL12 ligand greatly enhances both cancer cell growth and migration leading to metastasis [13, 19, 20] . Eighth, it would be advantageous if the peptide antagonist were able to disrupt the cell membrane lipid bi-layer to increase membrane fluidity (thinning) thus inferring with cell surface chemokine receptor clustering/ aggregation and subsequent intracellular signal transduction [22] .
Requirements for a Decoy

Synthetic Peptide Decoy Ligands for CXCR4
Several synthetic peptide antagonist/inhibitor [23] . A second peptide antagonist termed Plerixafor (AMD3100) was reported to decrease the metastatic potential in animal cancer models [24] .
Peptide T140 is a decoy receptor ligand which was reported to suppress tumor cell invasion into surrounding cells [25] ; while a TN14003 peptide was shown to inhibit both tumor cell invasion and migration [26] . [33] . One such AFP peptide sequence on the AFP third domain fragment has been isolated, purified, characterized, and assayed for biological activity [34, 35] . This 34-amino acid peptide and its subfragments have been termed the Growth Inhibitory Peptides (GIP) and were found to interact with the CXCR4 receptor [34] . In the present commentary, AFP-derived-peptide fragments are presented as example peptide decoy ligands for the CXC4 receptor for use on both primary tumor cells and their metastatic counterparts. In addition to the 34-mer GIP, the author (GJM) has previously developed a 9-mer subfragment of GIP termed P149c, an effective inhibitor of estrogen (E2)-induced cancer growth [35, 36] . Later, subsequent investigators modified P149c into a 9-mer cyclic peptide named AFPep, which also suppressed E2-induced cancer growth [37] . However, unlike GIP, both P149c and AFPep lack significant anti-metastatic capabilities [38] [39] [40] . M to 10 -10 M GIP [38] [39] [40] . A further advantage of GIP as a CXCR4 blocking agent is that it can inhibit platelet aggregation by 95% in assays employing adenosine diphosphate, arachidonic acid, or collagen-III as stimulators [38, 39] . In effect, this activity could serve to reduce or hinder tumor cell-induced platelet aggregation, thus preventing intravascular tumor cell clustering. In contrast, neither P149c or AFPep had any effect on platelet aggregation [38] . GIP might also [49] . A further study reported that GIP fragments block BC cell adherence to multiple extra-cellular matrix (ECM) proteins during tumor cell migration [39] [40] .
Biological Activities of AFP-derived
Tumor cells are known to invade and travel through the ECM spaces using tank-like traction movements to enhance mobility. In this regard, it was found that AFP-DP fragments were capable of inhibiting 40 to 50%
of tumor cell adhesion to multiple ECM cell proteins via binding to collagen IV, fibrinogen, fibronectin, thrombospondin, laminin, and vitronectin [38, 39, 46] .
In that same study, GIP was reported to inhibit tumor cell migration and cell spreading by 60% in BC cell cultures [38] . Thus, AFP-DPs have been previously 
